期刊文献+

丙戊酸钠对卵泡内膜细胞雄激素分泌及相关甾体合成酶改变的影响 被引量:6

Effect of Valprovate on Androgen Production and Correlative Steroidogenesis Enzyme mRNA Expression in Thecal Cells
下载PDF
导出
摘要 目的:研究丙戊酸钠(VPA)对卵泡内膜细胞睾酮生成以及细胞色素P45017α羟化酶(CYP17)、胆固醇侧链裂解酶(P450scc)和类固醇激素急性调节蛋白(StAR)mRNA的影响。方法:采用猪的卵泡内膜细胞进行体外原代培养,并给予不同浓度的VPA(0mg/L、50mg/L、100mg/L和250mg/L)处理,48h后收集培养液,采用ELISA法检测细胞睾酮的分泌,采用荧光实时RT-PCR(TaqMan.assay)方法检测卵泡内膜细胞中CYP17、P450scc和StARmRNA表达。结果:VPA刺激了卵泡内膜细胞睾酮的分泌(P<0.05),且CYP17(P<0.01)、P450scc(P<0.01)和StAR(P<0.01)mRNA表达增加。结论:VPA可直接作用于卵泡内膜细胞,改变CYP17、P450scc和StARmRNA表达,引起雄激素的分泌变化。临床上长期服用VPA的癫痫妇女出现类似于PCOS患者的生殖内分泌功能紊乱,可能与该药物本身作用有密切联系。 Objective: To investigate the effect of valproate on testosterone and CYP 17, P450scc and StAR mRNA expression in porcine thecal cells in vitro. Methods: The thecal cells were isolated from normal porcine ovaries and cultured with DMEM-F12 (1.1) medium and treated with various concentrations of sodium valprovate (0 mg/L, 50 mg/L, 100 mg/L, 250 mg/L). The culture media were collected after 48 h for testosterone measurements by ELISA, CYP17, P450scc and StAR mRNA in thecal cells were detected by real-time RT-PCR. Results: Valprovate caused increase of testosterone (P〈0.05), and significantly increased of CYP17 (P〈0.01), P450scc (P〈0.01) and StAR (P〈0.01) mRNA expression were observed in cultured cells. Conclusions: Valprovate can directly work on the thecal ceils: valprovate increased testosterone secretion by inducing CYP 17, P450scc and StAR mRNA expression in thecal cells. The occurrence of polycystic ovaries syndrome and endocrine disorders in women taking valprovate for epilepsy may be attributed to valprovate itself.
出处 《生殖与避孕》 CAS CSCD 北大核心 2005年第11期655-659,共5页 Reproduction and Contraception
基金 国家科技部重点"973"项目资助课题(No.2002CB512908) 江苏省高校自然科学研究项目(No.02KJB320008)
关键词 丙戊酸钠 卵泡内膜细胞 多囊卵巢综合征 睾酮 甾体生成酶 valproate thecal cells polycystic ovaries syndrome testosterone steroidogenesis enzyme
  • 相关文献

参考文献20

  • 1Rasgon NL, Altshuler LL & Gudeman D. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry, 2000, 61(3): 173 -8.
  • 2Isojarvi JI, Laatikainen T J, Pakarinen A J, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med, 1993, 329(19):1 383-8.
  • 3Isojarvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate treated women.Am J Med, 2001, 111(4):290-6.
  • 4Tauboll E, Wojtowicz AK, Ropstad E, et al. Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro. Reprod Toxicol, 2002, 16(3):319-25.
  • 5Nelson VL, Legro RS, Strauss JF, etal. Augmented androgen production is a stable steroidogenic phenotype of propagatedtheca cells from polycystic ovaries. Mol Endocrinol, 1999, 13(6): 946-57.
  • 6Jakimiuk AJ, Weitsman SR, Navab A, et al. Luteinizing hormone receptor, steroidogenesis acute regulatory protein,and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab, 2001, 86(3):1 318-23.
  • 7Franks S, Gharani N &McCa rthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update, 2001, 7(4):405-10.
  • 8Kahsar-Miller MD, Conway-Myers BA, Boots LR, et al.Steroidogenic acute regulatory protein (StAR) in the ovaries of healthy women and those with polycystic ovary syndrome.Am J Obstet Gynecol, 2001, 185(6): 1 381-7.
  • 9Wood JR, Nelson-Degrave VL, Jansen E, et al. Valproateinduced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics, 2005, 20(3):233-43.
  • 10O'Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry,2002, 63(4): 322-30.

二级参考文献15

  • 1Elliott JL,Hosford SL,Demopoulos RI,et al.Endometrial adenocarcinoma and polycystic ovary syndrome: risk factors,management,and prognosis.South Med J,2001,94(5): 529-31.
  • 2Mikola M,Hiilesmaa V,Halttunen M,et al.Obstetric outcome in women with polycystic ovarian syndrome.Hum Reprod,2001,16(2): 226-9.
  • 3Norman RJ,Masters L,Milner CR,et al.Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.Hum Reprod,2001,16(9): 1 995-8.
  • 4Pan HA,Wu MH,Cheng YC,et al.Quantification of Doppler signal in polycystic ovary syndrome using threedimensional power Doppler ultrasonography: a possible new marker for diagnosis.Hum Reprod,2002,17( 1 ):201-6.
  • 5Loverro G,Vicino M,Lorusso F,et al.Polycystic ovary syndrome: relationship between insulin sensitivity,sex hormone levels and ovarian stromal blood flow.Gynecol Endocrinol,2001,15(2): 142-9.
  • 6Juul A,Holm K,Kastrup KW,et al.Free insulin-like growth factor- Ⅰ serum levels in 1430 healthy children and adults,and its diagnostic value in patients suspected of growth hormone deficiency.J Clin Endocrinol Metab,1997,82(8):2497-502.
  • 7Giudice LC.Insulin-like growth factor family in Graafian follicle development and function.J Soc Gynecol Investig,2001,8(1 Suppl Proceedings): S26-9.
  • 8Guercio G,Rivarola MA,Chaler E,et al.Relationship between the growth hormone/insulin-like growth factor-I axis,insulin sensitivity,and adrenal androgens in normal prepubertal and pubertal girls.J Clin Endocrinol Metab,2003,88(3): 1 389-93.
  • 9Diamond MP,Grainger D,Diamond MC,et al.Effects of methyltestosterone on insulin secretion and sensitivity in women.J Clin Endocrinol Metab,1998,83(12): 4 420-5.
  • 10Unluhizarci K,Karababa Y,Bayram F,et al.The investigation of insulin resistance in patients with idiopathic hirsutism.J Clin Endocrinol Metab,2004,89(6):2 741-4.

共引文献25

同被引文献84

  • 1闫妙娥,宋娟娟,吴效科.PCOS是卵巢对胰岛素超敏的综合征[J].生殖与避孕,2006,26(4):233-236. 被引量:11
  • 2洪青青,李路,程利南.胰岛素抵抗、脂肪因子与多囊卵巢综合征[J].生殖与避孕,2006,26(10):606-609. 被引量:7
  • 3李静,李丹,黄绍平.妥泰、丙戊酸钠对成年及幼年大鼠血清瘦素和胰岛素水平的影响[J].中国当代儿科杂志,2007,9(3):229-232. 被引量:4
  • 4吴逊.我国癫痫的诊断与治疗现状[J].中国现代神经疾病杂志,2007,7(3):201-203. 被引量:10
  • 5Barker DJ. The fetal and infant origins of adult disease. BMJ, 1990, 301(6 761): 11 111-?.
  • 6Widdowson EM, McCance RA. A review: new thoughts on growth. Pediatr Res, 1975, 9(3):154-6.
  • 7ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Hum Reprod, 2004, 19(1):41-7.
  • 8Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab, 2006, 91(11):4 237-45.
  • 9Abbott DH, Barnett DK, Bruns CM, et al. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update, 2005, 11(4):357-74.
  • 10Legro RS, Driscoll D, Strauss JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA, 1998, 95(25):14 956-60.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部